Indolent anti‐Hu‐associated paraneoplastic sensory neuropathy
Abstract
Paraneoplastic sensory neuropathy (PSN) usually runs a subacute progressive course, leaving the patient with severe sensory dysfunction in weeks to months. We describe five patients with PSN, high titers of anti-Hu antibodies (type 1 antineuronal nuclear autoantibodies), and an indolent clinical course. The patients had a median age of 55 years (range, 41 to 72). Four had small-cell (3) or undifferentiated large-cell (1) lung cancer. Patients presented with mild, asymmetric sensory symptoms; in two, the neuropathy was predominant in the arms. Two patients also had a visceral neuropathy causing gastrointestinal dysfunction. The PSN was stable or progressed very slowly without treatment for a median of 18 months (range, 5 to 32) and remained so after treatment with immunoglobulins (1 patient), chemotherapy (3), or both therapies (1). All patients were ambulatory, leading an independent life up until the time of the last visit or until death from the tumor (2 patients). The median follow-up was 36 months (range, 22 to 52). A paraneoplastic origin should be considered in patients with mild, very slowly progressive sensory neuropathies.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 1994 by the American Academy of Neurology.
Publication History
Published online: December 1, 1994
Published in print: December 1994
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Inflammatory sensory neuronopathies, Revue Neurologique, (2024).https://doi.org/10.1016/j.neurol.2023.12.012
- Clinical approach to diagnosis of paraneoplastic neurologic syndromes, Paraneoplastic Neurologic Disorders, (79-96), (2024).https://doi.org/10.1016/B978-0-12-823912-4.00007-4
- Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis, Brain Communications, 5, 5, (2023).https://doi.org/10.1093/braincomms/fcad247
- Update on Paraneoplastic Neuromuscular Disorders, Current Treatment Options in Neurology, 24, 7, (267-284), (2022).https://doi.org/10.1007/s11940-022-00722-7
- Approach to chemotherapy-induced peripheral neuropathy, Neuro-Oncology for the Clinical Neurologist, (356-370), (2021).https://doi.org/10.1016/B978-0-323-69494-0.00028-2
- Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review, Journal of Neurology, 269, 3, (1182-1194), (2021).https://doi.org/10.1007/s00415-021-10577-8
- Paraneoplastic Neurologic Syndromes, Abeloff's Clinical Oncology, (676-687.e5), (2020).https://doi.org/10.1016/B978-0-323-47674-4.00044-X
- Paraneoplastic peripheral neuropathies, Dysimmune Neuropathies, (177-197), (2020).https://doi.org/10.1016/B978-0-12-814572-2.00008-X
- Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles, Lung Cancer, 111, (150-163), (2017).https://doi.org/10.1016/j.lungcan.2017.07.025
- Neurological Complications of Lung Cancer, Cancer Neurology in Clinical Practice, (417-434), (2017).https://doi.org/10.1007/978-3-319-57901-6_22
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.